BALTIMORE, MD--(Marketwired - Jul 30, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that the poor side effect profile for an already approved malaria drug serves as a major boost to Plandai Biotechnology Inc.'s (
According to recent news reports, U.S. Army Staff Sgt. Robert Bales, who is facing sentencing by a military court for killing 16 civilians on a rampage in Afghanistan last year, might have faced a perfect storm of stress, which included the use of mefloquine hydrochloride, an antimalarial drug given routinely to soldiers in that part of the world. Mefloquine was developed by the U.S. military and has been used for more than three decades by the government to prevent and to treat malaria among soldiers and Peace Corps workers. It is estimated that tens of millions are treated with it today.
According to CBS News, the drug's history of dangerous side effects is just now coming to light. For example, a study of FDA adverse-event reports from 2004 to 2009 published in the journal PLOS One lists mefloquine as a drug that has been associated with violence toward others.
With such negative history, it is clear that the market needs a real alternative with a high degree of efficacy that does not carry a poor side effect profile. This alternative may ultimately arrive in the form of Plandai's Phytofare™ Catechin Complex. The Company recently announced incredible results from its second round of in vitro testing of Phytofare™ Catechin Complex, used to kill the malaria parasite plasmodium falciparum. The results of this independent investigation confirmed a twelve-times greater efficacy in killing the parasite. It should be noted that in this round the Company elected to use the complete Phytofare™ complex and not just the isolated EGCG (Epigallocatechin Gallate) catechin used in earlier studies.
Clearly, these results show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial. Moreover, the data may serve as a major boon to treating a disease which potentially impacts hundreds of millions of people and kills 600,000 in the African continent alone. Plus, since the product is derived from a botanical extract, the safety profile is exceedingly high.
As development milestones occur, it is not hard to envision the Phytofare™ Catechin Complex as a replacement for the potentially dangerous Mefloquine and its generic siblings, for use by tens of millions across the globe.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com .
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com .
About Plandai Biotechnology, Inc. (
Goldman Small Cap Research Rob Goldman Analyst 410-609-7100 rob@goldmanresearch.com
